|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Here, we demonstrate that NQO1-targeting prodrug β-lapachone triggers tumor-selective innate sensing leading to T cell-dependent tumor control.
|
31324798 |
2019 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Here, we present a treatment strategy that makes BER inhibition tumor-selective and NQO1-dependent for therapy of most solid neoplasms, particularly for pancreatic cancer.
|
26602448 |
2015 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Here, we used NQO1-knockout (KO) mice to investigate the role of NQO1 in both the aging process and tumor susceptibility, specifically in the context of CR.
|
29733330 |
2019 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
High levels of NQO1 expression were observed throughout xenograft tumors established from the NQ16 cell line.
|
15131056 |
2004 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
However, we did not find preferential targeting of the active NQO1 allele in tumors with LOH at 16q.
|
18416817 |
2008 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In summary, RH1 can be effective in killing cells containing high levels of DTD and may be useful in treating tumors expressing this enzyme.
|
15090746 |
2004 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
In the case of MMC, however, the work presented here demonstrates that genotyping of individuals with respect to NQO1 is unlikely to be beneficial in terms of predicting tumor responses to MMC.
|
11709197 |
2001 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
It has been proposed that low molecular weight substance(s) can diffuse from tumor cells into surrounding normal cells and activate the expression of the NQO1 gene.
|
8375015 |
1993 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
JNK-NQO1 axis drives TAp73-mediated tumor suppression upon oxidative and proteasomal stress.
|
25341038 |
2014 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Leveraging an NQO1 Bioactivatable Drug for Tumor-Selective Use of Poly(ADP-ribose) Polymerase Inhibitors.
|
27960087 |
2016 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Low NQO1 mRNA and protein levels were observed in the TP53 mutated subgroup compared to others tumors (p < .05) and in silico analyses of The Cancer Genome Atlas data further indicated that NQO1 mRNA levels were lower in serous compared to endometrioid copy-number high EC.
|
30908539 |
2019 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
NAD(P)H:quinone oxidoreductase 1 (NQO1) is a key enzyme involved in defence against reactive forms of oxygen and inhibition of neoplasia.
|
15476858 |
2004 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
NAD(P)H:quinone oxidoreductase 1 (NQO1) regulates the stability of the tumor suppressor WT p53.
|
15809436 |
2005 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
NAD(P)H:quinone oxidoreductase 1 (NQO1) is elevated in several human tumors.
|
16532285 |
2006 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
NAD(P)H:quinone oxidoreductase1 (DT-diaphorase or NQO1) is a flavoprotein that promotes obligatory two-electron reduction of quinones, preventing their participation in redox cycling, oxidative stress, and neoplasia.NQO1 is ubiquitously expressed.
|
7620221 |
1994 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Notably, NQO1 inhibitor significantly enhanced the antitumor effects of THC in ESCC PDX tumors.
|
30737573 |
2019 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Our data showed that (1) the frequency of C609T NQO1 was significantly increased in TNM stage III HCC patients; (2) no significant association was found between p53 expression and C609T polymorphism of NQO1 gene; and (3) a tumor/non-tumor (T/N) ratio > 1.27 of NQO1 expression revealed by real-time qPCR analyses was positively correlated with poorer survival in patients with tumors >5 cm, suggesting that an increase of NQO1 expression may be an indicator of advanced tumor progression.
|
19688691 |
2009 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Previous studies have shown that depleting tumor-NQO1 potentiates anoikis and inhibits growth of NSCLC.
|
29291405 |
2018 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Protection from tumor formation is associated with elevation of Phase II enzymes, including glutathione (GSH) transferase and NAD(P)H:quinone oxidoreductase (DT-diaphorase) in experimental carcinogenesis models in vivo.
|
9815750 |
1997 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Quinone oxidoreductase (DT-diaphorase) levels rise in the human tumors but fall in the mouse; the extent of both changes is very dramatic.
|
9659582 |
1998 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Release of Lapa selectively increases tumor site-specific generation of H<sub>2</sub>O<sub>2</sub> via NAD(P)H: quinone oxidoreductase 1 (NQO1) catalysis.
|
31397998 |
2019 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Releasing β-lapachone first from the CARNs selectively increases the ROS level in cancer cells via NAD(P)H:quinone oxidoreductase-1 (NQO1) catalysis, which induces the cascade amplification release of DOX and overcomes multidrug resistance (MDR) in cancer cells, producing a remarkably improved therapeutic efficacy against MDR tumors with minimal side effects.
|
28833669 |
2017 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Secondary objectives were assessment of toxicity, pharmacokinetic determination of RH1 and pharmacodynamic assessment of drug effect through measurement of DNA cross linking in peripheral blood mononuclear cells (PBMCs) and tumour, DTD activity in tumour and NAD(P)H:quinone oxidoreductase 1 (NQO1) polymorphism status.
|
21378203 |
2011 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The FANCD2-associated survival effect was most pronounced in hormone receptor positive, HER2-negative tumors, and in tumors with above-median NQO1 expression.
|
23897704 |
2013 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The positive rate of NQO1 was related with clinical stage and lymph node metastasis, and the strongly positive rate of NQO1 protein was significantly correlated with tumor size, poor differentiation, advanced clinical stage and lymph node metastasis in NSCLC.
|
25880877 |
2015 |